SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Vyant Bio, Inc. (VYNT) .
Criteria proven by this page:
- VALUE (0/100, Fail) — the composite valuation score falls below the 60/100 threshold required to pass.
Overall SharesGrow Score: 18/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — VYNT
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio1.71
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-3.87
Book Value / Share$0.00
Revenue / Share$0.11
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-396.90 |
$6.61M |
$-12.37M |
-187.2% |
| 2014 |
$-263.85 |
$10.2M |
$-16.64M |
-163.2% |
| 2015 |
$-293.97 |
$18.04M |
$-20.18M |
-111.9% |
| 2016 |
$-149.45 |
$27.05M |
$-15.8M |
-58.4% |
| 2017 |
$-151.58 |
$29.12M |
$-20.88M |
-71.7% |
| 2018 |
$-111.98 |
$27.47M |
$-20.37M |
-74.2% |
| 2019 |
$-17.40 |
$7.31M |
$-6.71M |
-91.8% |
| 2020 |
$-18.50 |
$867K |
$-9.2M |
-1060.7% |
| 2021 |
$-10.19 |
$1.15M |
$-46.1M |
-4015.2% |
| 2022 |
$-3.87 |
$666K |
$-22.69M |
-3406.9% |
